X

Trial Profile

EMPA-TROPISM Trial: Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms ATRU-4; EMPA-TROPISM

Most Recent Events

13 Nov 2023 Insights from this study presented at the American Heart Association Scientific Sessions 2023.
17 Nov 2020 Results presented at the American Heart Association Scientific Sessions 2020
09 Nov 2020 Primary endpoint (LV-end diastolic volume (EDV)) has been met as per results published in the Journal of the American College of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com